Alto Neuroscience ANRO ALTO-300 — Direct external program expenses:

Other product segments

Similar metrics at other companies

IDYAIDE034 — External Clinical Development Expenses

$6.81M+17,816%

IDYAIDE397 — External Clinical Development Expenses

$3.52M-6.0%

IDYAIDE849 — External Clinical Development Expenses

$4.77M+1,026%

IDYAIDE161 — External Clinical Development Expenses

$1.61M-34.4%

NUVLNVL-330 — Direct Expenses Related To Program

$6.83M+72.3%

WVEAATD Program — Research And Development Expense

$1.75M+21.0%

Questions, answered.

What is Alto Neuroscience's ALTO-300 — direct external program expenses:?

Alto Neuroscience (ANRO) reported ALTO-300 — direct external program expenses: of $1.51M in Q1 2026.

How has Alto Neuroscience's ALTO-300 — direct external program expenses: changed year-over-year?

Alto Neuroscience's ALTO-300 — direct external program expenses: increased by 63.4% year-over-year, from $922K to $1.51M.

What is the long-term trend for Alto Neuroscience's ALTO-300 — direct external program expenses:?

Over 2 years (2023 to 2025), Alto Neuroscience's ALTO-300 — direct external program expenses: has grown at a 20.7% compound annual growth rate (CAGR), from $3.07M to $4.47M.

What does ALTO-300 — direct external program expenses: mean?

This metric represents the direct, out-of-pocket costs incurred for the clinical development and research activities specifically attributable to the ALTO-300 therapeutic candidate. It encompasses expenditures such as contract research organization fees, clinical trial site costs, and manufacturing expenses required to advance the program through its current clinical stage. Monitoring these expenses provides insight into the capital intensity and resource allocation efficiency of the specific drug development pipeline.